Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

460
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
460
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

368
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
368
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sedation Strategies, Drugs, and Protocols Used in Catheter Ablation of Atrial Fibrillation: A Focused Review.

Reviews in cardiovascular medicine·2026
Same author

Trends in sudden death-attributed mortality across Europe, 2010-2020: a retrospective population-based analysis.

The Lancet regional health. Europe·2026
Same author

Machine learning prediction of outcome following pulsed-field atrial fibrillation ablation: patient selection and risk factors.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Rationale and Design of the PREDICT-CCM Study: Predictive Value of Dobutamine Stress Echocardiography for Clinical Response to Cardiac Contractility Modulation Therapy in a Multicenter Italian Cohort.

Journal of clinical medicine·2026
Same author

Effectiveness and Safety of Early Rhythm Control in Patients With Atrial Fibrillation and Chronic Kidney Disease.

Journal of the American College of Cardiology·2026
Same author

Trajectories of coronary sinus pacing cathode to predict cardiac resynchronization therapy outcome: The TRAJECTORIES study.

Heart rhythm·2026

Related Experiment Video

Updated: Mar 24, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

Anticoagulation Issues in Patients with AF.

Antonio Rossillo1, Andrea Corrado, Paolo China

  • 1Cardiovascular Department, Ospedale dell'Angelo, Mestre-Venice, Italy.

Cardiac Electrophysiology Clinics
|March 5, 2016
PubMed
Summary

For atrial fibrillation (AF) patients, discontinuing anticoagulation after ablation may be safe if CHADS2 score is ≥2 and left atrial function is normal. Further trials are needed to confirm this stroke risk strategy.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

3.2K

Related Experiment Videos

Last Updated: Mar 24, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

3.2K

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Stroke risk assessment is vital for atrial fibrillation (AF) management.
  • Novel oral anticoagulants offer advantages over warfarin, including safety and convenience.
  • Anticoagulation strategies post-atrial fibrillation ablation require further investigation.

Purpose of the Study:

  • To evaluate the feasibility of discontinuing oral anticoagulation therapy after successful AF ablation.
  • To identify patient subgroups who may safely stop anticoagulation based on stroke risk scores and left atrial function.

Main Methods:

  • Review of existing literature on anticoagulation in AF patients.
  • Analysis of novel oral anticoagulants versus warfarin in terms of efficacy and safety.
  • Assessment of criteria for anticoagulation discontinuation post-AF ablation, including CHADS2 score and left atrial function.

Main Results:

  • Novel oral anticoagulants show comparable or better outcomes than warfarin for stroke prevention.
  • These agents offer simpler administration and no need for routine monitoring.
  • Discontinuation of anticoagulation appears feasible in select AF patients post-ablation (CHADS2 ≥2, normal LA function).

Conclusions:

  • Novel oral anticoagulants represent a significant advancement in AF stroke prevention.
  • A strategy of discontinuing anticoagulation post-ablation may be viable for specific patient profiles.
  • Larger prospective randomized trials are essential to validate the safety and efficacy of this discontinuation strategy.